Summary
The AdvaMed Conference will bring together international MedTech executives with regulatory, reimbursement, business development, legal, IP, marketing, quality, compliance, and other key responsibilities. Goodwin Procter is high-level sponsor.
Related Content
- AlertJuly 24, 2024
Common FDA Bioresearch Monitoring (BIMO) Violations: Updates from FY 2023 to Now
- InsightJuly 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2024 and Beyond
- AlertJune 4, 2024
Form SHL: What You Need to Know
- AlertMay 29, 2024
Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance
- AlertMay 20, 2024
FDA Finalizes Rule and Sets Course to Phase In Oversight of Laboratory Developed Tests
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightOctober 13, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA’s Proposed Phaseout Policy – Key Considerations & Open Questions
- InsightOctober 6, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule
- Press ReleaseJune 13, 2024
Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement
- Awards and RankingsJune 6, 2024
Chambers USA 2024 Recognizes Goodwin Practices and Lawyers for Exceptional Client Service
- Press ReleaseMay 29, 2024
Akili Interactive to Be Acquired by Virtual Therapeutics
- Press ReleaseMay 2, 2024
Mariana Oncology To Be Acquired by Novartis For $1 Billion Upfront, And Up To $750 Million in Milestones
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Awards and RankingsMarch 20, 2024
The American Lawyer Names Rachael Bushey and Jennifer Porter 2024 Dealmakers of the Year
- In the PressMarch 6, 2024
Eidos Therapeutics Signs Exclusive License Agreement with Bayer